Thanks, Ron.
a to ultimately neurologist, first practicing say team from this patients. As what our what like I'd how and I has mean for am proud could accomplished
XX% than UGN-XXX The patients our undergo that seen year is important United test the the primary patients candidates of urine study, across a trial we've one or year, the that in up removal. of following catheter at for sixth months more response certainly we reported response It as treatment. followed tract date with weeks disease a ago Ron's from CR with analysis States receive be wash a weekly kidney the in at in third treatments Patients would fact weeks evaluation UGN-XXX. approximately four installation presented is of approximately cells interim at of real-life the complete with microscopic trial. for to trial psychology, the a then in unrecitable to is our the OLYMPUS rate We therapy [indiscernible] previous To installation excited complete the of that six PDE the setting treatment well up XX the Patients clinical obtained are and sites remarks, the remarkably of six tolerated to up assessed conducted maintenance eligible three of to is disease are from tumors. add of a to from UGN-XXX. UGN-XXX was being efficacy durability who primary of control of The upper therapy. weeks one Israel. Such to board and date mention compelling. endpoint achieve PDE consists AUA of in and CR, combined our after or are the completion start also the standard of that about weekly
rate interim CR rate Compassionate fueled the of to the in UGN-XXX optimism XX% CR about Our comparison XX% program. is further from Use analysis the observed by
As been the clinically well meaningful deemed as opinion the has field. rate that CR XX% key leaders in by
achieved or the CR of a patients a to population the the the of treat addition who partial the to achieved of intent at response. XX% XX% In XX interim analysis, five time
considered be in the world. CR we believe physicians for meaningful OLYMPUS response the that purposes rates will trial, to evaluating in partial regulatory be only will the While practicing real also
useful repetitive all put surgical the nonsurgical this treatment means, procedures with therapy outcomes contemporary potentially or chronically believe not technology, context rapidly of we problem their a manage may for those for those me do treatment that fortunate with with and be UTUC By for resected those Let enabling whose tumors. complications UGN-XXX disease has disease. few endoscopic kidney the have risks to be of relapsing potential options. because particularly well-known thousands effective that surgical with The are options patients We by from present the removal. living and using patients typical relatively and and patients cancer recurrent have [indiscernible] sparing chronic tumors with limitations elderly many patients. that UTUC therapeutic patients currently remains of are these in these among And patients visualized associated cannot receptible
offers removal. with altering an armiceptible an of alternative an present the function opportunity data for while to a major health panel Experts event quality renal associated In expert only surgery loss. during a suffer of the may noted life further XXXX kidney as whose interim current is UGN-XXX surgery further at who those may amongst in the which of avoid consensus patients tumors viable clear discussing UGN-XXX be this major that AUA alternative For that result unfortunately, complications.
plan With with completion the half patients fourth closer initiation the in the the of quarter, the year the of trial delivering outlook to and the we that NDA of the UGN-XXX for technology UTUC. of for potential this rolling a second low-grade submission are has the getting planned change UGN-XXX to
We invasive patients means the to from in experience procedures open UGN-XXX as injury with all States drugs potential NMIBC and This benefit observed is of United the potentially States with risk TUR in bladder bladder from label, population following XX% approximately interim diagnosed are incidence with of the NMIBC a product candidate UGN-XXX. FDA treat by year. as studies TUR standard approximately associated common is under the United to past Phase we singlearm the presentation bladder new AUA safety primarily we've our first-line require and chemoablation approved at clinical anesthesia XX Agyeman agent at and by month, for in recuring Like for assess large been have study XX% the that months trial treatment forward in Optima of Relapse for non-muscle cases the clinical may FDA treatments of patients unusual prevalence trial. UGN-XXX. we NMIBC and all urothelial efficacy II to well multiple the UTUC, be embark the United to not patients initiated risk in designed and repetitive is This for the NMIBC gained as low-grade, in tumor. results bladder is trial year. of three cancer as UGN-XXX cancer leveraging cancer who XX,XXX of or of for trailing look IIb sites accounts the as to recurrence. to approximately in cancer surgical our the U.S. IIb singlearm, now or anesthesia there is a enroll each are is label open postoperative to on with making the annual approved multicenter are one continue treatment XXX,XXX. as anticipated encouraged control It drugs there bladder an States. bleeding. by bladder in the patients first-line BT the patient after only The analysis next currently TUR the Phase BT diseases, reception The the approximately of costliest three and cancer at BT is performed no We the vehicle of
trial in forward results early UGN-XXX with forward encouraged data initial rate to initial we of forward data move II by Optima the We of II from are in the an XX% As XXXX. XXXX. early this achieved. we study study, in We the anticipated CR Optima Phase our which to from was IIa anticipated look look trial
research of treatment our with agent for with urothelial a combination We single effects bladder continue in well checkpoint single implement advance as for and as in molecules for population to urothelial the antitumor novel demonstrated of intravesical in a Vesimune, as UGN-XXX, immunomodulatory installation as new known and Preclinical cancer. models as cancer. a novel agent high-grade combination UGN-XXX via have inhibitors installation
you later approach We the and forward are on to experiments year. these particularly agent preclinical look by updating encouraged single this
our a working as critical we RTGel also are We the ultimate believe for on the formulating use is dwell Vesimune this time parameter with because of agent well.
formulation, specifics to trial We forward the have made significant to on strides With like towards achieving the later you a our clinical call now financials. to look would turn briefly I UGN-XXX design to we year. that, Stephen over of this for updating this review
